CLINICAL ROLE -
FDA Grants Accelerated Approval to Tovorafenib for Pediatric Patients With BRAF-Mutated LGG
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
Read More
Expert: Nonprofit Organization Medical Brigades Supply Care to Community Honduras
Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.
Study Finds Relationship Between Uncontrolled Severe Asthma, Exacerbations and Health Care Resource Use
The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer
Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.
Iptacopan Demonstrates 38.3% Proteinuria Reduction in Patients With IgAN
Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.
Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Considerations When Treating Migraines in Gender Diverse Patients Receiving Gender-Affirming Hormone Therapy
The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.
Condition Watch: Asthma
HSSP Model Can Reduce Financial Toxicity of Oral Oncology Treatment
PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.
Study Examining Glofitamab With GemOX in Patients With R/R DLBCL Meets Primary Endpoint
Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.
FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC
With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.
Positive Data Demonstrates Gepotidacin is Non-Inferior to Alternative Treatment in GC
In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.
Climate Change Increases Rate of Infectious Diseases, Expert Says
Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.
FDA Grants Fast Track Designation for TLX101-CDx, an Investigational Glioma Imaging Product
The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.
Study Details Benefits, Therapeutic Effects of Medical Marijuana on Patients’ Quality of Life
The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.
Extension Trial Analysis Shows Long-Term Safety, Efficacy of Atogepant in Patients With Migraines
The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.
Study: Asthma Diagnosis in Children Does Not Appear Linked to COVID-19 Diagnosis
The authors note that additional research needs to be conducted to confirm whether the findings are consistent in adult patients.
FDA Grants Orphan Drug Designation for the Active Ingredient in MVD Vaccine
Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.
COVID-19 Pandemic Brought Changes, Requiring Significant Adjustments in Health Systems
Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.
Insights, Future Considerations in FLT3 Inhibitors Following Allo-HCT in Patients With AML
In this NCCN session, James M. Foran, MD, described the different FLT3 inhibitors that are available for FLT3-mutated AML, as well as considerations for the future.
New, Emerging Treatment Options for Patients With Multiple Myeloma
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.
FDA Updates Approval of Antiseizure Medication Cenobamate Allowing for Alternative Administration Methods
In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.
Researchers Develop ADC Combination Therapy to Target TRBC1-Expressed Hematologic Cancers
The antibody drug conjugate was used in combination with the anti-cancer drug SG3249, and demonstrated efficacy in mouse models after 1 week.
FDA Approves Benralizumab to Treat Pediatric Patients Aged 6 to 11 Years With Severe Asthma
Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.
Study Suggests Patients With Low-Risk CLL May Stop Specialized Follow-Up Visits
The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
Venetoclax With 5-Azacytidine Effective in Treating Patients With Multiple Myeloma
Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.
Investigators Find Piezo1 Has Potential for the Future of Asthma Treatment
Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.
FDA Approves Dolutegravir/Lamivudine for Treatment of Adolescents With HIV-1 Infection
The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.
